Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03221296
Other study ID # 17-5055
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 27, 2017
Est. completion date August 23, 2018

Study information

Verified date October 2018
Source University Health Network, Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A feasibility study of a vestibular rehabilitation program in a sample of cognitively impaired clinical patients to guide future trials.


Description:

This is a feasibility study to gather preliminary data on a vestibular rehabilitation program. All participants who visit UHN memory clinic with a diagnosis of mild/moderate cognitive impairment due to Alzheimer's or vascular disease or both and have had falls will be asked to participate. If agree to be contacted they will receive a consent form.

All agreeable participants shall be screened for vestibular impairment through the following tests: Dix-Hall pike test, Head Impulse Test, Head Shake test, test of Dynamic Visual Acuity. In addition, participants will complete the MoCA to assess cognitive functioning. A score lower than 15 will exclude the participant.

After determining the population who is eligible for this study and willing to participate, participants shall move to baseline assessment. At baseline, measurements of balance, gait, and dynamic visual acuity in addition to questionnaires about dizziness felt, confidence in performing activities without falling, depression and quality of life, shall be completed.

Immediately after baseline, participants will begin their treatment arm, depending on if they have been put in the vestibular group or control group. Participants in the vestibular arm will be taught vestibular exercises and asked to perform vestibular exercises for 3 sessions daily, 3-10 minutes/session. Participation in vestibular exercises shall be recorded via a log by their caregiver. During the 12 weeks, these diaries shall be kept with the participant caregiver. Caregivers shall be followed up bi-weekly to ensure that participants are completing the exercises, and logging their participation.

At the end of the 12 weeks, participants will be reassessed with the same measures from baseline in addition to the head impulse test and test of dynamic visual acuity. The investigators shall also administer a final questionnaire (Problematic Experiences of Therapy Scale) to see what may have prevented completion of therapy or caused issues.

Participants that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.

3-months after final assessments (6 months after start), all participants shall be contacted to see if there were any falls/near fall experiences.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date August 23, 2018
Est. primary completion date August 23, 2018
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Elderly people ages 65 and older

- English speaking

- Can log their participation or have a caregiver log on their behalf

- Mild/moderate dementia [(1) Alzheimer's disease, (2) small vessel vascular dementia not related to stroke and (3) mixed dementia of Alzheimer's or small vessel vascular not related to stroke] or mild/moderate cognitive impairment

- Vestibular Impairment

Exclusion Criteria:

- Neurological disease (e.g. seizures, stroke, hemorrhage, central nervous system tumor, multiple sclerosis)

- Being diagnosed with a psychiatric disorder (e.g. Major depression episode, post-traumatic stress disorder, generalized anxiety disorder, schizophrenia, bipolar disorder etc.)

- Those with a current inner ear infection

- Those with severe neck arthritis

- Those with Post-Concussion Syndrome

- Severe cognitive impairment as defined by a MoCA <15

- Following etiologies of dementia: Dementia due to Lewy bodies, Parkinson's disease, Huntington's Disease, Frontotemporal Dementia, Normal Pressure Hydrocephalous

Study Design


Intervention

Behavioral:
Vestibular Training (Intervention Group)
Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.

Locations

Country Name City State
Canada Toronto Western Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of falls/near fall experiences through the Falls Video Analysis Questionnaire (FVAQ) Measured by comparing the test score change from baseline to follow up at 3 months and again at 6 months to determine if the therapy worked 3 months and again 6 months after baseline
Secondary Change in levels of dizziness through the Dizziness Handicap Inventory (DHI) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in perceived level of confidence through the Activities Specific Balance Confidence Scale (ABC) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in quality of life through The Geriatric Depression Scale (GDS) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Cognitive status through the Montreal Cognitive Assessment (MoCA) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in physical functioning through the head impulse test (HIT) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Number of patients who can successfully complete Head Impulse Test (HIT) Shall be measured by proportion of participants completing test (did not need to stop for any reason) 3 months
Secondary Number of patients who can successfully complete Head Shake Test (HST) Shall be measured by proportion of participants completing test (did not need to stop for any reason) 3 months
Secondary Number of patients who can successfully complete Dynamic Gait Index (DGI) Shall be measured by proportion of participants completing test (did not need to stop for any reason) 3 months
Secondary Number of patients who can successfully complete the test of dynamic visual acuity (DVA) Shall be measured by proportion of participants completing test (did not need to stop for any reason) 3 months
Secondary Number of patients who can successfully complete the modified clinical test of sensory interaction on balance (mCTSIB) Shall be measured by proportion of participants completing test (did not need to stop for any reason) 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Dizziness Handicap Inventory (DHI) Shall be measured by percentage of test items completed 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Montreal Cognitive Assessment (MoCA) Shall be measured by percentage of test items completed 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Quality of Life in Alzheimer's Disease (QOL-AD) Shall be measured by percentage of test items completed 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the World Health Organization Quality of Life - BREF (WHOQOL-BREF) Shall be measured by percentage of test items completed 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Activities Specific Balance Confidence scale (ABC) Shall be measured by percentage of test items completed 3 months
Secondary Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Geriatric Depression Scale (GDS) Shall be measured by percentage of test items completed 3 months
Secondary Number of patients who successfully adhered to the vestibular rehabilitation program through the Problematic Experiences of Therapy scale (PETs) filled out by both, or either one of, the patient or caregiver 3 months
Secondary Attrition Rate Will be measured as the percentage of those who reached follow-up compared to those who completed baseline 3 months
Secondary Number of patients willing to participate Determined by the proportion of patients saying yes out of those contacted 3 months
Secondary Change in quality of life through The World Health Organization Quality of Life - BREF (WHOQOL-BREF) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in quality of life through The Quality of Life in Alzheimer's Disease (QOL-AD) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in physical functioning through the head shake test (HST) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in physical functioning through the dynamic visual acuity (DVA) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in physical functioning through the modified clinical test of sensory interaction on balance (mCTSIB) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
Secondary Change in physical functioning through the dynamic gait index (DGI) Measured by comparing the test score change from baseline to follow up at 3 months 3 months
See also
  Status Clinical Trial Phase
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Completed NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Phase 2
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT00165763 - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Phase 4
Completed NCT00621647 - Seroquel- Agitation Associated With Dementia Phase 3
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Active, not recruiting NCT03804229 - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Phase 3
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02453932 - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Phase 3
Completed NCT00947531 - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Phase 4
Not yet recruiting NCT03702543 - Managing Vascular Dementia Risk Factors With SymTrend Phase 1
Enrolling by invitation NCT02147652 - Personalized Music Therapy and Agitation in Dementia N/A
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT06034509 - Cognitive and Vascular Functioning Following TBI
Recruiting NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity N/A
Not yet recruiting NCT01466543 - Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Phase 2
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A